Evan David Seigerman
Stock Analyst at BMO Capital
(3.72)
# 856
Out of 4,412 analysts
17
Total ratings
43.75%
Success rate
12.43%
Average return
Main Sectors:
Top Industries:
11 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Initiates: Outperform | $163 | $126.85 | +28.50% | 1 | Apr 12, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,055 → $1,082 | $883.20 | +22.51% | 3 | Feb 5, 2024 | |
| ABBV AbbVie | Maintains: Outperform | $187 → $195 | $159.62 | +22.17% | 1 | Feb 5, 2024 | |
| AMGN Amgen | Upgrades: Outperform | $286 → $326 | $269.98 | +20.75% | 2 | Dec 19, 2023 | |
| MRK Merck & Co. | Upgrades: Outperform | $132 | $131.20 | +0.61% | 1 | Oct 27, 2023 | |
| PFE Pfizer | Maintains: Outperform | $44 → $33 | $25.40 | +29.92% | 3 | Oct 16, 2023 | |
| GPCR Structure Therapeutics | Maintains: Outperform | $40 → $83 | $38.94 | +113.15% | 1 | Oct 3, 2023 | |
| MORF Morphic Holding | Maintains: Outperform | $106 → $52 | $28.07 | +85.25% | 2 | Sep 28, 2023 | |
| CADL Candel Therapeutics | Maintains: Outperform | $9 → $3 | $6.39 | -53.05% | 1 | May 15, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $40 → $70 | $6.42 | +990.34% | 1 | Dec 12, 2022 | |
| LLY Eli Lilly | Maintains: Outperform | $369 → $396 | $733.51 | -46.01% | 1 | Sep 6, 2022 |
Novo Nordisk
Apr 12, 2024
Initiates: Outperform
Price Target: $163
Current: $126.85
Upside: +28.50%
Regeneron Pharmaceuticals
Feb 5, 2024
Maintains: Outperform
Price Target: $1,055 → $1,082
Current: $883.20
Upside: +22.51%
AbbVie
Feb 5, 2024
Maintains: Outperform
Price Target: $187 → $195
Current: $159.62
Upside: +22.17%
Amgen
Dec 19, 2023
Upgrades: Outperform
Price Target: $286 → $326
Current: $269.98
Upside: +20.75%
Merck & Co.
Oct 27, 2023
Upgrades: Outperform
Price Target: $132
Current: $131.20
Upside: +0.61%
Pfizer
Oct 16, 2023
Maintains: Outperform
Price Target: $44 → $33
Current: $25.40
Upside: +29.92%
Structure Therapeutics
Oct 3, 2023
Maintains: Outperform
Price Target: $40 → $83
Current: $38.94
Upside: +113.15%
Morphic Holding
Sep 28, 2023
Maintains: Outperform
Price Target: $106 → $52
Current: $28.07
Upside: +85.25%
Candel Therapeutics
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $6.39
Upside: -53.05%
Replimune Group
Dec 12, 2022
Maintains: Outperform
Price Target: $40 → $70
Current: $6.42
Upside: +990.34%
Eli Lilly
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $733.51
Upside: -46.01%